ANDA 207514, held by Amneal Pharms. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 207514 (Norethindrone Acetate And Ethinyl Estradiol And Ferrous Fumarate), held by Amneal Pharms, was first approved by FDA on Sep 11, 2017, with 2 approved supplements and 0 published complete response letters.
Melodetta 24 Fe is indicated for use by females of reproductive age to prevent pregnancy. The efficacy of Melodetta 24 Fe in women with a body mass index (BMI) of more than 35 kg/m 2 has not been evaluated. Melodetta 24 Fe is an estrogen/progestin COC indicated for use by women to prevent pregnancy The efficacy in women with a body mass index of more than 35 kg/m 2 has not been evaluated (1, 8.8)
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 11, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Norethindrone Acetate And Ethinyl Estradiol And Ferrous Fumarate0.02MG;1MG · tablet;oral | Ethinyl Estradiol; Norethindrone Acetate | Discontinued |
| Jun 22, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jun 22, 2023 | Supplement 13Labeling · Standard review | Approved | None posted |
| Sep 11, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters